Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THDBH130 in Hyperuricemia With or Without Gout – Phase 2
CTR20222979Phase 2Completed
- Sponsor
- Nanjing Mingde New Drug Research and Development
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of THDBH130 in hyperuricemia, gout, sponsored by Nanjing Mingde New Drug Research and Development. Started Nov 2022; status: completed.
02
Drugs
THDBH130
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on CTR20222979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222979.